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ABSTRACT
Objectives: Fungal infections cause significant
global morbidity and mortality. We have previously
described the UK investments in global infectious
disease research, and here our objective is to
describe the investments awarded to UK institutions
for mycology research and outline potential funding
gaps in the UK portfolio.
Design: Systematic analysis.
Setting: UK institutions carrying out infectious
disease research.
Primary and secondary outcome measures:
Primary outcome is the amount of funding and
number of studies related to mycology research.
Secondary outcomes are describing the investments
made to specific fungal pathogens and diseases,
and also the type of science along the R&D value
chain.
Methods: We systematically searched databases and
websites for information on research studies from
public and philanthropic funding institutions awarded
between 1997 and 2010, and highlighted the
mycology-related projects.
Results: Of 6165 funded studies, we identified 171
studies related to mycology (total investment £48.4
million, 1.9% of all infection research, with mean
annual funding £3.5 million). Studies related to
global health represented 5.1% of this funding (£2.4
million, compared with 35.6% of all infectious
diseases). Leading funders were the Biotechnology
and Biological Sciences Research Council (£14.8
million, 30.5%) and Wellcome Trust (£12.0 million,
24.7%). Preclinical studies received £42.2 million
(87.3%), with clinical trials, intervention studies and
implementation research in total receiving £6.2
million (12.7%). By institution, University of
Aberdeen received most funding (£16.9 million,
35%). Studies investigating antifungal resistance
received £1.5 million (3.2%).
Conclusions: There is little translation of
preclinical research into clinical trials or
implementation research in spite of substantial
disease burden globally, and there are few UK
institutions that carry out significant quantities of
mycology research of any type. In the context of
global health and the burden of disease in low-
income countries, more investment is required for
mycology research.
INTRODUCTION
Fungal pathogens account for signiﬁcant
burden of human disease globally.
Prevalence of serious fungal infection in
Brazil is estimated at 1.7% of the population,
1.9% in Ireland and the burden of fungal
disease in China is thought to be among the
greatest in the world.1 Cryptococcal meningi-
tis has been estimated to cause over 600 000
deaths globally per annum, with a compar-
able mortality rate to tuberculosis in
sub-Saharan Africa.2 Aspergillosis and
Candidiasis have relatively high mortality
rates and cause in excess of 200 000 and
400 000 life-threatening infections each year.3
Incidence of coccidiomycosis has increased
sharply in recent years.4 However, estimates
can widely vary, as the WHO has no pro-
gramme on fungal infection, and most
public health agencies, apart from the US
Centers for Disease Control and Prevention,
conduct little or no mycological surveil-
lance.3 Mycology infections also have a role
to play in allergic and inﬂammatory
diseases.5 6
Strengths and limitations of this study
▪ This is the first study to present detailed system-
atically collected data and rigorously quantify
funding related to mycology research invest-
ments made to UK institutions.
▪ Our results highlight clear gaps in the UK
research portfolio and illustrate some priority
areas for funders and policymakers.
▪ We also highlight strengths in preclinical
research in the UK.
▪ We do not have private sector data, and their
contributions to areas such as diagnostics and
vaccine development are currently unknown.
Further international data is required to assess
the true research gaps related to global mycol-
ogy investments.
▪ Categorising is subjective, and we do not take
into account funding of overheads or the impact
of the introduction of full economic costing.
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There are some treatment options available for fungal
disease,7 with relatively low levels of resistance to cur-
rently available medicines, but very few options for pre-
vention—there are no existing vaccines. The majority of
the burden appears to be in low-income and
middle-income countries—countries with weak health
systems, and thus suitable diagnostics and distribution of
treatments may be lacking. In high-income countries, it
is immunosuppressed individuals who are particularly
vulnerable to invasive fungal disease.7
UK research institutions received at least £2.6 billion
of public and philanthropic funding to carry out infec-
tious disease research between 1997 and 2010 from a
variety of national and international funding sources.8
This funding was spent on all types of science along the
research pipeline, from preclinical studies to clinical
trials and implementation research. However, there
appear to be relatively few UK research centres with a
focus on mycology research. We report here the
research funding that was awarded to UK institutions
speciﬁcally for mycology-related research, along with
temporal trends and the relative proportions allocated.
We assess how closely the topics funded relate to the
clinical and public health burden of mycology disease,
seeking to identify potential funding gaps that policy-
makers and funders can be encouraged to focus on in
future, and areas where the UK has clear research
strengths.
METHODS
The analyses in this article focused on studies funded in
a 14-year period (1997–2010 inclusive) that were rele-
vant to, or had speciﬁc mention of, fungal pathogens.
The methods have been described in detail elsewhere,8
but are reiterated brieﬂy here. The overarching dataset
was obtained from several sources of public and charit-
able funding for infectious disease research studies,
including the Wellcome Trust, Medical Research
Council and other research councils, UK government
departments, European Commission, Bill and Melinda
Gates Foundation and other research charities. Data col-
lection was via (1) downloading all data from the funder
website and manually ﬁltering the infectious disease
studies; or (2) searching open access databases on the
funder website for infection-related keyword terms or
(3) contacting the funder directly and requesting details
of their infection studies. Funders were identiﬁed
through author’s knowledge of the R&D landscape and
searches on the Internet. The majority of data extraction
was performed by author MGH, with support from
author JRF and other colleagues. Each study was
assigned to as many primary disease categories as appro-
priate.9 Within each category, topic-speciﬁc subsections
(including speciﬁc pathogen or disease) were documen-
ted. Global health studies were deﬁned as those where
the study had a clear reference to another country (eg,
cryptococcal meningitis in South Africa). Studies were
also allocated to one of four R&D categories: preclinical;
phase 1, 2 or 3; product development; and implementa-
tion and operational research (including surveillance,
epidemiology and statistical and modelling projects).
Funders were either considered in their own right, or
for convenience, some were grouped into categories
such as research charities and government departments.
We used 26 funder categories.9 No private sector
funding was included in this analysis as the publicly avail-
able data from these sources were very limited and con-
sidered to be under-representative. Studies were
excluded if (1) they were not immediately relevant to
infection; (2) they were veterinary infectious disease
research studies with no clear implications for zoonoses;
(3) they concerned the use of viral vectors to investigate
non-communicable diseases; (4) they were grants for
symposia or meetings or (5) they included UK research-
ers, but with the funding awarded to and administered
through a non-UK institution. Unfunded studies were
also excluded. Grants awarded in a currency other than
pounds sterling were converted into UK pounds using
the mean exchange rate in the year of the award. All
awards were adjusted for inﬂation and reported in 2010
UK pounds. Data management was carried out in
Microsoft Excel and Access (versions 2000 and 2007)
and statistical analysis in Stata (V.11).
RESULTS
We identiﬁed 6165 studies funded within the 14-year
period and covering all infectious disease research
representing a total investment of £2.6 billion.
Investments for mycology research were £48.4 million
across 171 studies (1.9 and 2.8% of total funding and
study numbers, respectively). Mean annual funding was
£3.5 million, ranging from £0.7 million in 1998 to £10.4
million in 2008.
By pathogen, Candida received the greatest investment
(£22.8 million, 76 studies) followed by Aspergillus (£4.8
million, 26 studies), with fewer studies relating to crypto-
coccosis (9 studies, £3.5 million) and Paracoccidioides (4
studies, all awarded over 10 years ago, £462 478; tables 1
and 2). Median funding per mycology project was
£138 257 (IQR £41 162–338 222), and the mean was
£238 067 (SD £447 190). There was no clear temporal
trend (ﬁgure 1A). By type of science along the R&D
value chain, £42.2 million (87%) was directed towards
preclinical research, and £2.6 million (5%) towards
implementation and operational research. The remain-
ing investments were for either phases I–IV trials or
product development studies (ﬁgure 1B, tables 1 and 2).
There were nine studies with a clear focus on global
health, totalling £2.5 million. There were also four
studies on paediatric mycology infection (£0.1 million),
ﬁve related to coinfection with HIV (£2.8 million), 27
related to therapeutics (£4.5 million) and 14 studies on
antimicrobial resistance (£1.5 million). There were ﬁve
studies classiﬁed as related to dermatological fungal
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i- nfection, totalling £0.4 million. Four studies considered
fungal pathogens in the context of healthcare-associated
infections. There were no studies looking at mycology
and vaccinology.
The greatest total investment was awarded by the
Biotechnology and Biological Sciences Research Council
(BBSRC), with 36 awards totalling £14.8 million, fol-
lowed by the Wellcome Trust (£12.0 million, 49 studies).
University of Aberdeen was awarded £17.0 million
(35%), and Imperial College London £4.5 million
(9.4%).
DISCUSSION
The UK has received investments from public and phil-
anthropic funding sources totalling at least £48.4 million
across 171 studies during the 14-year time period of this
study, and this is approximately 2% of total investments
related to all infectious disease. This ﬁgure is compar-
able to estimates made elsewhere.7 The vast majority of
investments are in preclinical research, and the BBSRC
and the Wellcome Trust provided the majority of
funding. Candida is the most studied pathogen. The
University of Aberdeen is clearly the leading UK institu-
tion for mycology research, receiving over one-third of
the total investments.
There is very little mycology research that has a spe-
ciﬁc focus on global health (£2.5 million, 5.1%). This is
an unexpected ﬁnding, given that across all infectious
diseases 35.6% of funding had a clear global health
component.8 The lower investment may be a result of
almost all of the research being preclinical, and thus
hard to attribute to a global health category (most of
the global health research in the larger study is transla-
tional in nature). This general lack of translation of
research along the research pipeline from the preclin-
ical stage through to more translational components is
something for policymakers and funders to focus on in
the short-term and medium-term future.
The lack of high-quality routine data, diagnostics, and
that many fungal pathogens are commonly only found
in resource-poor settings, may also contribute to this
apparent lack of global health research. The few invest-
ments, for example, related to Paracoccidioides are all
from over 10 years ago. There are no clear research
investments in vaccinology and mycology disease in our
dataset, but several studies relate to therapeutics.
Antimicrobial resistance is not currently considered too
severe (relative to areas such as many Gram-negative
pathogens or tuberculosis) as there are efﬁcacious treat-
ment options for treating fungal pathogens. However,
there are sometimes limited options available and drug
interactions and toxicity can be problematic, and preva-
lence of resistance in Candida10 and Aspergillus11 is
increasing. Thus, it is surely prescient to assess the likely
future burden of resistance to antifungal drugs now,
rather than waiting for the problems to emerge, particu-
larly considering the historic underinvestment in
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antimicrobial resistance generally.12 There appears to be
almost no investment on studies that speciﬁcally looked
at fungal infections and coinfection with HIV—given
the severity of the rising burden in this area, it would
seem to be another important area for increased focus.
Brieﬂy assessing the global numbers of estimated deaths
and life-threatening infections, perhaps cryptococcal
disease is relatively the most underfunded fungal
disease, for example, as compared with Aspergillus and
Candida infection (though they all of course warrant
increased investment). Nosocomial infections were also
neglected, with just four studies speciﬁcally investigating
this area and none of them focusing on Candida or
Aspergillus infection. The complete absence of any
public or philanthropic funding for vaccine research is
concerning, and though therapeutics were the subject of
27 studies, they often received only small amounts of
investment.
The University of Aberdeen clearly leads on receiving
investments for human mycology research. Other institu-
tions are some way behind in terms of total funding
received, and given the relatively small sums of funding
involved, just one or two principal investigators transfer-
ring institutions can easily impact on which universities
will receive future investments. Our analysis does not
document investments awarded to international institu-
tions where there was a UK collaborator receiving funds,
and this does highlight the need for international data-
bases of mycology research funding that can draw
together such collaborations, and whether other coun-
tries are ﬁlling apparent gaps in the UK research
portfolio.
Our study has several limitations, which have been
highlighted and discussed in detail elsewhere.8 There
was little publicly available data from the pharmaceutical
industry. Hence, there is a data gap in relation to
funding of clinical trials and development of vaccines
and diagnostics, which the pharmaceutical and biotech-
nology industries are ﬁnancing. We rely on the original
data being complete and accurate, and are unable to
take into account distribution of funds from the lead
institution to collaborating partners, nor can we assess
quantity of each award given to overheads or the impact
of the introduction of full economic costing. Also,
assigning studies to categories is a subjective and imper-
fect process—although we used two researchers when
assigning ﬁnding to categories to reduce interobserver
error.
This is the ﬁrst national systematic analysis of all infec-
tious disease research investments. There are no other
national databases of systematically collected research
funding, so comparisons with the mycology research
investments of other countries are not possible. Thus,
there is a need for similar analyses across the European
Union, the USA and other countries, to allow for con-
struction of a global database of mycology research pro-
jects, which will allow highlighting of existing expertise,
technology and outputs, and help to promote inter-
national collaboration in areas of high need and reduce
duplication of research.
CONCLUSIONS
The UK has clear strengths in preclinical mycology
research, but there is little investment in more transla-
tional projects further down the R&D value chain, and
funders and policymakers should seek to address this.
There are also gaps in some of the neglected high-
burden mycological infections such as Cryptococcus.
Improved global surveillance and data collection for all
fungal pathogens will help in targeting research funds
towards the most appropriate and impactful proposals.
Table 2 Detailed breakdown of funding by disease, themed area and corresponding type of science along the R&D value
chain
Disease
Preclinical Phases I–III Product development Operational
Study
numbers Funding
Study
numbers Funding
Study
numbers Funding
Study
numbers Funding
Mycology 125 £42 244 247 5 £2 008 147 11 £1 536 372 30 £2 615 719
Pathogen
Aspergillus 20 £4 526 214 1 £6721 0 £0 5 £320 923
Candida 70 £21 598 686 0 £0 0 £0 6 £1 183 245
Cryptococcosis 5 £1 668 260 1 £1 234 684 3 £578 591 0 £0
Paracoccidioides 4 £462 478 0 £0 0 £0 0 £0
Infection group*
Respiratory 26 £5 620 674 3 £1 789 554 3 £578 591 6 £410 477
Dermatology 2 £342 617 0 £0 1 £8588 2 £55 801
STIs 3 £297 416 0 £0 0 £0 2 £41 760
*For pathogens with multiple modes of entry and sites of impact, for example, Candida, studies could only be applied to infection groups if
they explicitly mentioned the route of transmission or site of infection. This was often not the case particularly with preclinical studies.
STIs, sexually transmitted infections.
4 Head MG, Fitchett JR, Atun R, et al. BMJ Open 2014;4:e004129. doi:10.1136/bmjopen-2013-004129
Open Access
 group.bmj.com on January 12, 2014 - Published by bmjopen.bmj.comDownloaded from 
Resistance to antifungal drugs is not yet as urgent a
priority as for bacterial infections, but there must be pro-
activity in addressing the likely future resistance burden.
Epidemiological and economic studies will help more
accurately quantify the health and ﬁnancial burden of
fungal infections, and partnerships with the private
sector are urgently needed to introduce vaccines and
new diagnostics that can be implemented in resource-
poor settings. In the short term, investments in oper-
ational research, for how best to distribute existing
effective treatments to areas of high need, would be
useful.
Funders based in other countries should also be
encouraged to release their funding data for similar sys-
tematic analyses, to allow for construction of a global
database of previous and current mycology research pro-
jects. Improved surveillance systems and national surveys
to collect more rigorous data on incidence and preva-
lence of fungal infections would be useful in allowing
comparisons of investments in research with the health
and economic burden of mycological disease.
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